Using Magnetic Pulses to Combat Insomnia Among Military Personnel

Summary: Researchers at the University of Arizona are exploring a novel, nondrug treatment for insomnia among military personnel using magnetic brain stimulation. Supported by a $3 million grant from the Department of Defense, the study led by William “Scott” Killgore aims to reduce excessive brain activity that interferes with sleep by targeting the default mode…

Read More

Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz

Summary: A US court upheld the FDA’s approval of Avadel Pharmaceuticals’ Lumryz, a once-nightly oxybate for narcolepsy, rejecting Jazz Pharmaceuticals’ challenge on orphan status and clinical superiority grounds. The ruling confirms Lumryz’s orphan drug exclusivity based on its clinical advantages over Jazz’s twice-nightly oxybate. Key Takeaways: Court Upholds FDA Approval: The US court ruled in…

Read More

ŌURA Buys Sparta Science to Boost Enterprise Capabilities

Summary: ŌURA has acquired Sparta Science to enhance its Oura Teams platform, aiming to deliver scalable, data-driven health insights for enterprise clients, including healthcare and government organizations. Leveraging Sparta Science’s Trinsic platform, ŌURA will integrate multiple data sources to support personalized health tracking and population-level analytics, with added technical expertise from former Sparta Science team…

Read More

Survey Shows Americans Underestimate Risks of Drowsy Driving

Summary: Ahead of Drowsy Driving Prevention Week, the National Sleep Foundation’s survey reveals that while 70% of Americans avoid driving after drinking, only 40% take similar precautions when sleep-deprived. Drowsy driving, which causes thousands of crashes and fatalities annually, is linked to impaired driving abilities comparable to drunk driving. Key Takeaways: Low Awareness of Drowsy…

Read More

Jazz Presents New Phase 4 Data on Xywav’s Impact on Narcolepsy and IH

Summary: At the 37th annual Psych Congress, Jazz Pharmaceuticals presented results from the phase 4 DUET trial on low-sodium Xywav, showing its effectiveness in treating excessive daytime sleepiness and improving sleep outcomes for adults with narcolepsy and idiopathic hypersomnia. Findings indicated notable improvements in polysomnography measures like nighttime awakenings and sleep stage stability, reinforcing Xywav’s…

Read More